MX2020004100A - Metodo para generacion in vivo de anticuerpos multiespecificos a partir de anticuerpos monoespecificos. - Google Patents

Metodo para generacion in vivo de anticuerpos multiespecificos a partir de anticuerpos monoespecificos.

Info

Publication number
MX2020004100A
MX2020004100A MX2020004100A MX2020004100A MX2020004100A MX 2020004100 A MX2020004100 A MX 2020004100A MX 2020004100 A MX2020004100 A MX 2020004100A MX 2020004100 A MX2020004100 A MX 2020004100A MX 2020004100 A MX2020004100 A MX 2020004100A
Authority
MX
Mexico
Prior art keywords
antibodies
multispecific antibodies
generation
vivo generation
monospecific
Prior art date
Application number
MX2020004100A
Other languages
English (en)
Inventor
Ulrich Brinkmann
Klaus Mayer
Steffen Dickopf
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2020004100A publication Critical patent/MX2020004100A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

En la presente se reporta un método para la generación de anticuerpos multiespecíficos directamente en la superficie celular en el sitio de acción mediante una reacción de intercambio de mitades de anticuerpos entre dos 2/3-IgG o dos 2/3-BiFab desestabilizadas por la mitad mediante mutaciones perturbadoras asimétricas que fomentan la generación de anticuerpos biespecíficos o multiespecíficos de longitud completa correctamente ensamblados. El método se realiza en la ausencia de enlaces de disulfuro de región bisagra en las 2/3-IgG o 2/3-BiFab iniciales.
MX2020004100A 2017-10-30 2018-10-29 Metodo para generacion in vivo de anticuerpos multiespecificos a partir de anticuerpos monoespecificos. MX2020004100A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17199086 2017-10-30
PCT/EP2018/079523 WO2019086362A1 (en) 2017-10-30 2018-10-29 Method for in vivo generation of multispecific antibodies from monospecific antibodies

Publications (1)

Publication Number Publication Date
MX2020004100A true MX2020004100A (es) 2020-07-24

Family

ID=60413028

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020004100A MX2020004100A (es) 2017-10-30 2018-10-29 Metodo para generacion in vivo de anticuerpos multiespecificos a partir de anticuerpos monoespecificos.

Country Status (12)

Country Link
US (2) US12180279B2 (es)
EP (1) EP3704145A1 (es)
JP (2) JP7438942B2 (es)
KR (1) KR102831164B1 (es)
CN (1) CN111372947B (es)
AU (1) AU2018358883B2 (es)
BR (1) BR112020007736A2 (es)
CA (1) CA3078676A1 (es)
IL (1) IL274071B2 (es)
MX (1) MX2020004100A (es)
TW (1) TWI832824B (es)
WO (1) WO2019086362A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020004100A (es) * 2017-10-30 2020-07-24 Hoffmann La Roche Metodo para generacion in vivo de anticuerpos multiespecificos a partir de anticuerpos monoespecificos.
CN110507824A (zh) * 2018-05-21 2019-11-29 荣昌生物制药（烟台）有限公司 一种抗间皮素抗体及其抗体药物缀合物
JP7812230B2 (ja) * 2019-04-25 2026-02-09 エフ． ホフマン－ラ ロシュ アーゲー ポリペプチド鎖交換による抗体由来ポリペプチドの生成
BR112021020859A2 (pt) * 2019-04-25 2022-01-04 Hoffmann La Roche Conjuntos de polipeptídeos, método para gerar um polipeptídeo, polipeptídeo heterodimérico, primeiro polipeptídeo precursor heterodimérico e segundo polipeptídeo precursor heterodimérico
TW202120556A (zh) 2019-08-08 2021-06-01 美商再生元醫藥公司 新穎抗原結合分子型式
JP7568326B2 (ja) * 2020-06-01 2024-10-16 マストバイオ株式会社 二重特異抗体またはその抗原結合断片、及びそれを製造する方法
EP4259194A4 (en) * 2020-12-10 2025-03-19 Invenra Inc. Orthogonal mutations for heterodimerization
EP4263595A1 (en) * 2020-12-18 2023-10-25 F. Hoffmann-La Roche AG Precursor proteins and kit for targeted therapy
WO2024104933A1 (en) * 2022-11-15 2024-05-23 F. Hoffmann-La Roche Ag Antigen binding molecules
WO2024156759A1 (en) * 2023-01-25 2024-08-02 F. Hoffmann-La Roche Ag Payload-bearing multispecific antibodies
EP4574839A1 (en) * 2023-12-22 2025-06-25 BioNTech SE Co-delivery system
TW202527999A (zh) 2023-11-10 2025-07-16 德商拜恩技術股份公司 共同遞送系統
CN117467025B (zh) * 2023-12-28 2024-04-16 上海鼎新基因科技有限公司 一种抗vegf和补体双功能融合蛋白及其应用

Family Cites Families (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
AU634186B2 (en) 1988-11-11 1993-02-18 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
ES2206447T3 (es) 1991-06-14 2004-05-16 Genentech, Inc. Anticuerpo humanizado para heregulina.
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
WO1993006217A1 (en) 1991-09-19 1993-04-01 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
FI941572A7 (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
EP0625200B1 (en) 1992-02-06 2005-05-11 Chiron Corporation Biosynthetic binding protein for cancer marker
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
DE69328430T2 (de) 1992-07-27 2001-01-25 The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer Zielgerichte liposome zur blut-hirne schranke
GB9221657D0 (en) 1992-10-15 1992-11-25 Scotgen Ltd Recombinant bispecific antibodies
PL174494B1 (pl) 1992-11-13 1998-08-31 Idec Pharma Corp Kompozycja farmaceutyczna do leczenia chłoniaka z limfocytów B i sposób wytwarzania kompozycji farmaceutycznej do leczenia chłoniaka z limfocytów B
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
EP2275119B1 (en) 1995-07-27 2013-09-25 Genentech, Inc. Stable isotonic lyophilized protein formulation
JP3266276B2 (ja) 1996-07-25 2002-03-18 ゲーエスエフ―フォルシュングスツェントゥルム・フューア・ウムヴェルト・ウント・ゲズントハイト・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 二重特異性抗体断片の簡易化した製造
ES2246069T3 (es) 1997-05-02 2006-02-01 Genentech, Inc. Procedimiento de preparacion de anticuerpos multiespecificos que tienen componentes comunes y multimericos.
US7951917B1 (en) 1997-05-02 2011-05-31 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
CA2323757C (en) 1998-04-02 2011-08-02 Genentech, Inc. Antibody variants and fragments thereof
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
NZ517906A (en) 1999-10-04 2003-01-31 Medicago Inc Cloning of genomic sequences encoding nitrite reductase (NiR) for use in regulated expression of foreign genes in host plants
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
CA2395660A1 (en) 1999-12-29 2001-07-12 Immunogen, Inc. Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
LT2857516T (lt) 2000-04-11 2017-09-11 Genentech, Inc. Multivalentiniai antikūnai ir jų panaudojimas
DE10121982B4 (de) 2001-05-05 2008-01-24 Lts Lohmann Therapie-Systeme Ag Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung
US20060252028A1 (en) 2002-08-16 2006-11-09 Hiroshi Ueda Method of assaying interaction between proteins
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
CA2507762C (en) 2002-12-03 2013-02-05 Blanchette Rockefeller Neurosciences Institute Artificial low-density lipoprotein carriers for transport of substances across the blood-brain barrier
CN103833854B (zh) 2002-12-16 2017-12-12 健泰科生物技术公司 免疫球蛋白变体及其用途
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
CA2530388A1 (en) 2003-06-27 2005-01-06 Biogen Idec Ma Inc. Modified binding molecules comprising connecting peptides
DE602004030811D1 (de) 2003-10-16 2011-02-10 Micromet Ag Multispezifische deimmunisierte cd3-bindende moleküle
AU2003280713A1 (en) 2003-11-04 2005-05-19 Chugai Seiyaku Kabushiki Kaisha Process for producing antibody
NZ583292A (en) 2003-11-06 2012-03-30 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
WO2005062916A2 (en) 2003-12-22 2005-07-14 Centocor, Inc. Methods for generating multimeric molecules
EP2357201B1 (en) 2004-04-13 2017-08-30 F. Hoffmann-La Roche AG Anti-P-selectin antibodies
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
AU2005299716B2 (en) 2004-10-22 2012-09-06 Amgen Inc. Methods for refolding of recombinant antibodies
TWI544076B (zh) 2005-03-31 2016-08-01 中外製藥股份有限公司 A method of manufacturing a polypeptide that controls assembly
WO2007062466A1 (en) 2005-11-29 2007-06-07 The University Of Sydney Demibodies: dimerisation-activated therapeutic agents
PL1999154T3 (pl) 2006-03-24 2013-03-29 Merck Patent Gmbh Skonstruowane metodami inżynierii heterodimeryczne domeny białkowe
JP5144499B2 (ja) 2006-03-31 2013-02-13 中外製薬株式会社 二重特異性抗体を精製するための抗体改変方法
JP2009541275A (ja) 2006-06-22 2009-11-26 ノボ・ノルデイスク・エー／エス 二重特異性抗体の生産
ES2399075T3 (es) 2006-08-30 2013-03-25 Genentech, Inc. Anticuerpos multiespecíficos
CN101802015B (zh) 2007-03-29 2015-05-06 根马布股份公司 双特异性抗体及其制造方法
SG193868A1 (en) 2007-09-26 2013-10-30 Chugai Pharmaceutical Co Ltd Modified antibody constant region
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US8592562B2 (en) 2008-01-07 2013-11-26 Amgen Inc. Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects
EP3505636A1 (en) 2009-04-27 2019-07-03 OncoMed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
RU2522002C2 (ru) 2009-06-26 2014-07-10 Ридженерон Фармасьютикалз, Инк. Легковыделяемые биспецифические антитела с природным иммуноглобулиновым форматом
US20130089554A1 (en) 2009-12-29 2013-04-11 Emergent Product Development Seattle, Llc RON Binding Constructs and Methods of Use Thereof
BR122021015749B1 (pt) 2010-04-20 2022-07-26 Genmab A/S Métodos in vitro para gerar uma proteína heterodimérica, para a seleção de um anticorpo biespecífico, método para produzir uma proteína heterodimérica, vetor de expressão, célula hospedeira procariótica, proteína heterodimérica, composição farmacêutica, e, uso de uma proteína heterodimérica
MX346731B (es) 2010-04-23 2017-03-30 Genentech Inc * Producción de proteínas heteromultiméricas.
US9527926B2 (en) 2010-05-14 2016-12-27 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
WO2012025530A1 (en) * 2010-08-24 2012-03-01 F. Hoffmann-La Roche Ag Bispecific antibodies comprising a disulfide stabilized - fv fragment
CA2815266C (en) 2010-11-05 2023-09-05 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the fc domain
HUE039703T2 (hu) 2011-08-23 2019-01-28 Roche Glycart Ag Bispecifikus antigénkötõ molekulák
BR112014010023B1 (pt) 2011-10-27 2023-11-21 Genmab A/S Método in vitro para a produção de um anticorpo biespecífico de comprimento total
SI2794905T1 (sl) 2011-12-20 2020-08-31 Medimmune, Llc Modificirani polipeptidi za ogrodja bispecifičnega protitelesa
CN107383197B (zh) 2012-04-20 2021-12-10 美勒斯公司 用于产生免疫球蛋白样分子的方法和手段
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
AU2014325063B2 (en) 2013-09-27 2019-10-31 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide heteromultimer
KR102357961B1 (ko) 2013-12-17 2022-02-08 제넨테크, 인크. 항-cd3 항체 및 이의 사용 방법
BR112016025393A2 (pt) 2014-06-12 2017-12-12 Hoffmann La Roche método para selecionar um anticorpo inteiro, pluralidade de anticorpos, uso de uma ou mais mutações de aminoácidos e anticorpo inteiro variante
SI3608337T1 (sl) 2014-08-04 2024-07-31 F. Hoffmann - La Roche Ag Biospecifične molekule za aktivacijo celic T in antigensko vezavo
ES2764111T3 (es) * 2014-12-03 2020-06-02 Hoffmann La Roche Anticuerpos multiespecíficos
JP6904902B2 (ja) 2014-12-05 2021-07-21 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ ドメイン交換抗体
KR101851380B1 (ko) 2015-10-12 2018-04-23 아주대학교산학협력단 효모접합을 이용한 항체 ch3 도메인 이종이중체 돌연변이쌍 제조 방법 및 이에 의하여 제조된 ch3 돌연변이체 쌍
EP3889175A1 (en) 2016-05-02 2021-10-06 F. Hoffmann-La Roche AG The contorsbody - a single chain target binder
JP7556687B2 (ja) 2017-02-24 2024-09-26 中外製薬株式会社 薬学的組成物、抗原結合分子、治療方法、およびスクリーニング方法
BR112020007154A2 (pt) * 2017-10-20 2020-09-29 F. Hoffmann-La Roche Ag método para produzir um polipeptídeo e polipeptídeos heterodimérico
MX2020004100A (es) * 2017-10-30 2020-07-24 Hoffmann La Roche Metodo para generacion in vivo de anticuerpos multiespecificos a partir de anticuerpos monoespecificos.

Also Published As

Publication number Publication date
US12180279B2 (en) 2024-12-31
CA3078676A1 (en) 2019-05-09
KR20200074195A (ko) 2020-06-24
US20200255522A1 (en) 2020-08-13
KR102831164B1 (ko) 2025-07-07
IL274071A (en) 2020-06-30
JP2021501181A (ja) 2021-01-14
CN111372947A (zh) 2020-07-03
CN111372947B (zh) 2025-08-15
JP2024001197A (ja) 2024-01-09
US20250206821A1 (en) 2025-06-26
IL274071B1 (en) 2025-06-01
JP7438942B2 (ja) 2024-02-27
TWI832824B (zh) 2024-02-21
WO2019086362A1 (en) 2019-05-09
AU2018358883A1 (en) 2020-04-23
AU2018358883B2 (en) 2025-09-25
EP3704145A1 (en) 2020-09-09
IL274071B2 (en) 2025-10-01
BR112020007736A2 (pt) 2020-10-20
TW201932494A (zh) 2019-08-16

Similar Documents

Publication Publication Date Title
MX2020004100A (es) Metodo para generacion in vivo de anticuerpos multiespecificos a partir de anticuerpos monoespecificos.
CL2021000630A1 (es) Métodos para producir un anticuerpo anti-c5 (divisional de la solicitud no. 201701585)
CL2019000082A1 (es) Anticuerpos específicos para la tau hiperfosforilada y sus métodos de uso.
EP4257613A3 (en) Bispecific checkpoint inhibitor antibodies
CO2019007046A2 (es) Moléculas de unión a antígeno biespecíficas que comprenden el clon 20h4.9 anti-4-1bb
AR109771A1 (es) Moléculas biespecíficas de unión a antígeno activadoras de células t
CL2017000954A1 (es) Moléculas de unión a antígeno biespecificas activadoras de células t
ECSP21069105A (es) Anticuerpos anti-trem2 y métodos para utilizarlos
CO2021012719A2 (es) Métodos para producción de células car-nk y uso de las mismas
PE20191812A1 (es) Compuestos y metodos para la reduccion celular especifica de tumor
AR111184A1 (es) Poliamidas y métodos para producir los mismos
AR106201A1 (es) Moléculas biespecíficas de unión a antígeno activadoras de células t
EP3592845A4 (en) NK-92 HANK003 MODIFIED CELLS FOR THE CLINIC
CO2019002607A2 (es) Biomarcadores de metabolitos para enfermedades asociadas con el sistema de activación por contacto
PE20180950A1 (es) Anticuerpos biespecificos especificos para un receptor de tnf coestimulador
BR112017024555A2 (pt) moduladores de ccr2
EA201690213A1 (ru) Композиции и способ лечения связанных с комплементом состояний
MX2017013383A (es) Prediccion de respuesta a alvocidib mediante perfilado mitocondrial.
NI202000087A (es) Anticuerpos ant-tmeff2 monoespecíficos y multiespecíficos y sus usos
CL2017001107A1 (es) Base de montaje para miembro de desgaste
AR100367A1 (es) Anticuerpos biespecíficos químicamente bloqueados
BR112019004449A2 (pt) heparina biossintética
BR112015030537A2 (pt) método para avaliar planos de estratégia de produção
ECSP11011190A (es) Anticuerpos monoclonales anti-rhd
AR115599A1 (es) Método y aparato para la preparación de un bien de ensilado y proceso de ensilaje